Elyamany Ghaleb, Awad Mohammed, Alsuhaibani Omar, Fadalla Kamal, Al Sharif Omer, Al Shahrani Mohammad, Alabbas Fahad, Al-Abulaaly Abdulaziz
Department of Hematology and Blood Bank, Theodor Bilharz Research Institute. ; Dept. of Central Military Laboratory, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
Dept. of Central Military Laboratory, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
Mediterr J Hematol Infect Dis. 2014 Jun 1;6(1):e2014038. doi: 10.4084/MJHID.2014.038. eCollection 2014.
The fms-like tyrosine kinase 3 (FLT3) gene is a member of the class III receptor tyrosine kinase family. Mutations of FLT3 were first described in 1997 and account for the most frequent molecular mutations in acute myeloid leukemia. Currently, there is no published data on FLT3 mutations in Saudi acute lymphoblastic leukemia (ALL) patients. In this retrospective study, we have examined a cohort of 77 ALL patients to determine the prevalence of FLT3 mutations and the possible prognostic relevance of these mutations in ALL patients. Correlations to other biologic factors such as karyotype, molecular mutations, and leukocyte count were also considered. FLT3 internal tandem duplication (ITD) mutations and point mutation in tyrosine kinase domain (D835) were analyzed in ALL patients, at diagnosis, by polymerase chain reaction (PCR). Two cases (2.6%, 2/77) were positive for FLT3 mutations; one was found to have FLT3/ITD and the other FLT3/D835. Our findings suggest that FLT3 mutations are not common in Saudi ALL and do not affect clinical outcome.
FMS样酪氨酸激酶3(FLT3)基因是III类受体酪氨酸激酶家族的成员。FLT3突变于1997年首次被描述,是急性髓系白血病中最常见的分子突变。目前,尚无关于沙特急性淋巴细胞白血病(ALL)患者FLT3突变的公开数据。在这项回顾性研究中,我们检测了77例ALL患者,以确定FLT3突变的发生率以及这些突变在ALL患者中可能的预后相关性。还考虑了与其他生物学因素的相关性,如核型、分子突变和白细胞计数。在诊断时,通过聚合酶链反应(PCR)分析ALL患者的FLT3内部串联重复(ITD)突变和酪氨酸激酶结构域(D835)中的点突变。2例(2.6%,2/77)FLT3突变呈阳性;1例为FLT3/ITD,另1例为FLT3/D835。我们的研究结果表明,FLT3突变在沙特ALL中并不常见,且不影响临床结局。